Goldman Sachs Maintains Buy on Pacific Biosciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on Pacific Biosciences (PACB) but lowers the price target from $9 to $7.

April 10, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Pacific Biosciences but lowers the price target from $9 to $7.
While the reduction in price target could suggest a tempered outlook on the stock's short-term price performance, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the ongoing endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100